Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Antimicrobial Resistance Diagnostics Industry Expected To Reach By 2029, Starting From 2025 Levels?
The antimicrobial resistance diagnostics market size has experienced robust expansion in recent years. This market is projected to expand from $4.10 billion in 2024 to $4.41 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.5%. Historically, this growth has been driven by factors such as the escalating occurrence of hospital-acquired infections, the increased inappropriate use of antibiotics in both human and animal populations, the expanding threat posed by multidrug-resistant organisms, the proliferation of public health surveillance initiatives, and the uptick in diagnostic testing for infectious diseases.
The antimicrobial resistance diagnostics market size is projected to experience robust expansion over the coming years, reaching $5.82 billion by 2029, with a compound annual growth rate (CAGR) of 7.2%. This growth throughout the forecast period is fueled by an escalating demand for swift diagnostic tools, a heightened awareness of antimicrobial stewardship, augmented government funding for resistance tracking, the broadening application of point-of-care testing, and an increasing necessity for early infection detection. Key trends anticipated during this period encompass technological enhancements in diagnostic platforms, innovations in methods for resistance gene detection, greater investment in research and development, the creation of portable testing devices, and advancements in multiplex and high-throughput testing.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25696&type=smp
What Are The Drivers Pushing New Developments In The Antimicrobial Resistance Diagnostics Market?
The increasing occurrence of drug-resistant infections is projected to fuel the expansion of the antimicrobial resistance diagnostics market in the future. These infections arise when bacteria, viruses, fungi, or parasites develop ways to withstand medicines that were formerly potent, rendering conventional treatments ineffective and infections more challenging to manage. The increasing widespread nature of drug-resistant infections stems from the excessive use of antibiotics in farming, where small amounts of antimicrobials are regularly incorporated into animal feed, fostering resistance capable of transmitting to humans via the food chain. Antimicrobial resistance diagnostics, including swift genetic tests and culture-dependent sensitivity evaluations, are crucial in confronting the escalating prevalence of drug-resistant infections by facilitating prompt detection of resistant disease-causing agents, directing specific treatments, and minimizing the improper application of broad-spectrum antibiotics. For example, in November 2023, a report from the UK Health Security Agency (UKHSA), a government body, indicated that the overall count of antibiotic-resistant infections in England increased from 55,792 cases in 2021 to around 58,224 in 2022, showing a 4% year-on-year rise in antimicrobial resistance across the country. Consequently, the increasing occurrence of drug-resistant infections is propelling the expansion of the antimicrobial resistance diagnostics market.
What Are The Primary Types Of Segments Analyzed In The Antimicrobial Resistance Diagnostics Market?
The antimicrobial resistance diagnostics market covered in this report is segmented –
1) By Product Type: Kits And Reagents, Instruments And Consumables
2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRntS), Other Pathogens
3) By Technology: Microbiology Culture, Immunoassay, PCR (Polymerase Chain Reaction), NGS (Next-Generation Sequencing), Mass Spectrometry, Rapid And Point Of Care, Other Technologies
4) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users
Subsegments:
1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Polymerase Chain Reaction (PCR) Reagents, Immunoassay Reagents, Stains And Dyes, Culture Media
2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines, Ultraviolet-Visible (UV-Vis) Spectrophotometers, Next-Generation Sequencing (NGS) Systems, Microarray Scanners, Automated Liquid Handlers, Sample Collection Tubes And Swabs
How Are Trends Influencing The Antimicrobial Resistance Diagnostics Market?
Major companies in the antimicrobial resistance diagnostics market are focusing on developing innovative products like multiplex polymerase chain reaction (PCR) assays, designed to concurrently detect multiple pathogens and resistance genes, thereby enhancing diagnostic efficiency and accuracy. Multiplex PCR technology integrates numerous sets of primers into a single reaction, enabling the identification of various DNA targets simultaneously, which significantly reduces both time and resource requirements. For instance, in May 2022, Vela Diagnostics, a Singapore-based molecular diagnostics company, introduced the PathoKey MP urinary tract infections (UTI) ID and antimicrobial resistance (AMR) PCR Test. This product allows for the simultaneous detection of 14 urinary tract infection pathogens and 14 antimicrobial resistance genes, supports both automated and manual workflows, and provides results in as little as four hours to facilitate rapid, lab-scale AMR profiling. The PathoKey MP UTI ID & AMR PCR Test is engineered to provide clinical labs with faster, high-throughput detection capabilities to guide early intervention and effective antibiotic therapy.
Who Are The Primary Competitors In The Global Antimicrobial Resistance Diagnostics Market?
Major companies operating in the antimicrobial resistance diagnostics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, bioMérieux S.A., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Seegene Inc., Alifax S.r.l., Accelerate Diagnostics Inc., Lumos Diagnostics Holdings Pty Ltd, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc., OpGen Inc., T2 Biosystems, Jiangsu Medomics Medical Technology Co. Ltd.
Download The Full Report For Exclusive Market Findings:
Which Geographies Are Emerging As Strong Markets For The Antimicrobial Resistance Diagnostics Industry?
North America was the largest region in the antimicrobial resistance diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Antimicrobial Resistance Diagnostics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25696&type=smp
Browse Through More Reports Similar to the Global Antimicrobial Resistance Diagnostics Market 2025, By The Business Research Company
Oncology Drugs Market 2025
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Oncology Drugs Market 2025
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Brain Tumor Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model